Dr. Janet Greeson, CEO of Samaritan stated, "We remain enthusiastically confident in the promise of SP01A.
Dr. Greeson, CEO of Samaritan Pharmaceuticals, stated, "We are completely excited about SP-233 (Caprospinol) as a totally new approach to treat Alzheimer's disease.
continued, "We have been aggressively pushing to file an investigational new drug (IND) application for Caprospinol and this is one of the many milestones we have had to achieve to get there."
Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "We are extremely pleased with our collaboration with Georgetown University, it gives us the ability to continually, build and grow, our pipeline of innovative drugs.
Dr. Janet Greeson - Chief Executive Officer, President and Director
Dr. Janet Greeson, Chairman, President and CEO, led the bold initiative that transformed Samaritan from a "one drug" Company to an innovative "Drug Development Pipeline" Biopharmaceutical Company.
strategically created a long-term value and growth model, with the Samaritan/Georgetown University collaboration; and intends to duplicate this growth model with other top tier Universities, as a solid strategy to continually build Samaritan's value and sustain its future profitability.
is a successful healthcare professional with over two decades of corporate experience focused on emerging growth situations, leadership development, and mergers and acquisitions.
Although she has worked with Samaritan for nine years, as CEO for the past four years she has demonstrated a relentless perseverance and determination to succeed in the face of unrelenting change.
is extremely motivated and equipped to attack problems and seize realistic opportunities, with capability, courage and confidence.
Dr. Greeson is a co-inventor of 18 patent applications, and presently has nine "peer reviewed" journal publications.
is a best selling author of "It's Not What You Are Eating, It's What's Eating You"; and a renowned public speaker, whose guest appearances on numerous radio and TV Talk shows, has opened the door to tell the Samaritan story, in a concise and professional manner.
Dr. Greeson is an experienced growth "Model" developer.
In the past, Dr. Greeson
developed model "Addiction Rehab Programs" for the US Navy
, and went on privately, to develop and grow a nationwide "inpatient treatment program model" which she
later sold to Columbia/HCA (NYSE:COL).
Dr. Greeson has an eclectic past, once working with Mother Theresa and was privileged to be the U.S. Congressional Nominee for the State of Nevada in 1994, winning the primary without spending a dollar to campaign.
currently fulfills her
altruistic energies with the Samaritan Innovative Science Foundation
Dr. Greeson holds a BA, from Florida Technological University 1978; an MA from Rollins College 1979; a PhD from Columbia Pacific University 1987.
devotes substantially all of her
time to the affairs of Samaritan Pharmaceuticals